Long-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free status
<p>Abstract</p> <p>Background</p> <p>Methylphenidate (MPH), a psycho-stimulant, is the most widely administered drug for the pharmacological management of patients with attention deficit hyperactivity disorder (ADHD). This study attempts to determine whether sustainable...
Main Authors: | Huang Yu-Shu, Wang Liang-Jen, Chen Chih-Ken |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-11-01
|
Series: | BMC Psychiatry |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-244X/12/194 |
Similar Items
-
Attention Deficit Hyperactivity Disorder and Methylphenidate: When Society Misunderstands Medicine
by: David D. Kaminester
Published: (2020-12-01) -
A Quasi-Experimental Trial in Comparison of Duloxetine and Methylphenidate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder
by: Nasrin Dodangi, et al.
Published: (2016-06-01) -
Decreased Risk of Influenza in Child and Adolescent Patients with Attention-Deficit Hyperactivity Disorder Following Methylphenidate Treatment: A Nationwide Cohort Study in Taiwan
by: Lee H, et al.
Published: (2020-05-01) -
Decrease in brain complexity with methylphenidate treatment in boys diagnosed with attention deficit hyperactivity disorder: An entropy-based qeeg analysis
by: F.H. Çetin, et al.
Published: (2021-04-01) -
Neural Markers of Methylphenidate Response in Children With Attention Deficit Hyperactivity Disorder
by: Anne B. Arnett, et al.
Published: (2022-05-01)